NCT02980991View on ClinicalTrials.gov

Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

April 30, 2018

Conditions
Lung Adenocarcinoma
Interventions
DRUG

Pemetrexed

Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery

DRUG

Cisplatin

Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT02980991 - Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | Biotech Hunter | Biotech Hunter